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Abstract 
Due to an aging population, the incidence of dementia is steadily rising. The ability to identify early markers 
in blood, which appear before the onset of clinical symptoms is of considerable interest to allow early 
intervention, particularly in “high risk” groups such as those with Type 2 Diabetes (T2D). Here we present a 
longitudinal study of genome-wide DNA methylation in whole blood from 18 elderly individuals with T2D 
who developed pre-symptomatic dementia within an 18 month period following baseline assessment and 
18 age, sex and education matched controls who maintained normal cognitive function. We identified a 
significant overlap in methylomic differences between groups at baseline and follow-up, with eight CpG 
sites, being consistently differentially methylated above our nominal significance threshold prior to 
symptoms at baseline and at 18 month follow up, after a diagnosis of pre-symptomatic dementia. Finally 
we report a significant overlap between DNA methylation differences identified in converters, only after 
they develop symptoms of dementia, with differences at the same loci in blood samples from patients with 
clinically-diagnosed Alzheimer’s disease compared to unaffected controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. Introduction 
Alzheimer’s disease (AD) is a chronic, currently incurable, neurodegenerative disorder with more than 26 
million cases worldwide, and accounting for ~60% of dementia cases (Brookmeyer, et al., 2007).  With an 
increasingly aging population, new estimates for dementia incidence predict >115 million cases worldwide 
by 2050 (Prince, et al., 2013). AD is characterised by the accumulation of extracellular amyloid plaques, and 
intracellular neurofibrillary tangles, leading to selective neuronal cell loss, behavioural and personality 
changes and ultimately death after many years of suffering. Although much progress has been made in 
understanding the molecular pathology of AD, the treatments currently available only temporarily alleviate 
some symptoms and do not modify the underlying pathology. By the time an individual becomes 
symptomatic there is already considerable neuronal cell loss, plaque deposition and neurofibrillary tangle 
burden within the brain, which can appear years before a clinical diagnosis is made (Jack, et al., 2010). 
Although the majority of AD cases are sporadic, occur later in life (age>65 years) and have no known cause, 
the disease is associated with several vascular risk factors, especially type 2 diabetes mellitus (T2D) 
(Arvanitakis, et al., 2004,Stewart and Liolitsa, 1999), which more than doubles the risk of developing AD 
(Schnaider Beeri, et al., 2004). 
A number of studies have aimed to identify blood-based biomarkers for AD. These have identified changes 
in the abundance of plasma or serum proteins (Hye, et al., 2006,Hye, et al., 2014,O'Bryant, et al., 
2010,O'Bryant, et al., 2011,Ray, et al., 2007,Thambisetty, et al., 2008) and specific gene expression 
signatures (Booij, et al., 2011,Fehlbaum-Beurdeley, et al., 2012,Lunnon, et al., 2013,Rye, et al., 2011), some 
of which differentiate AD, and even persons with mild cognitive impairment (MCI), from elderly controls 
with normal cognition. Recently we have started to examine whether epigenetic (DNA methylation) 
changes are seen in white blood cells in AD sufferers compared to elderly non-demented control subjects 
(Lunnon, et al., 2014). 
The ability to identify early peripheral molecular signatures associated with the onset of dementia in “high 
risk” groups is of particular importance for the development of preventive interventions. To this end the 
aim of the current study was to identify DNA methylation differences in whole blood obtained from a 
longitudinal analysis of T2DM patients developing pre-symptomatic dementia symptoms over an 18 month 
period, compared to those remaining cognitively normal.  
 
 
 
 
2. Methods 
2.1 Subjects and Samples 
This study builds on the longitudinal Israel Diabetes and Cognitive Decline (IDCD) study, which investigates 
the effects of long-term T2D-related characteristics on cognitive decline (Ravona-Springer, et al., 2013).  
The IDCD study design and subject selection is described in detail in the Supplementary Methods.  The 
Clinical Dementia Rating (CDR) scale and neurological and psychiatric assessments were used to define 
intact cognition (CDR = 0) at study entry.  For the purposes of this study, we chose the first 18 subjects 
whose cognition at 18-months follow-up declined to CDR=0.5 (i.e. pre-symptomatic dementia; converters) 
confirmed by a multidisciplinary diagnostic consensus conference. Eighteen control subjects (non-
converters), i.e. individuals whose normal cognition was maintained at follow up based on a CDR=0 and 
confirmed in consensus conference, were matched to the converters for age, sex, and number of years of 
education. Subject characteristics are summarised in Supplementary Table 1.  
2.2 Methylomic Profiling 
Genomic DNA was isolated in individuals at baseline and follow up from whole blood stored in EDTA 
collection tubes using a standard phenol-chloroform extraction method and tested for degradation and 
purity prior to analysis. 500ng DNA from each sample was treated with sodium bisulfite using the Zymo 
EZ96 DNA methylation kit (Zymo Research, CA, USA) according to the manufacturer’s standard protocol. 
Samples were assessed using the Illumina Infinium HumanMethylation450K BeadChip (Illumina Inc., CA, 
USA) using the Illumina HiScan System (Illumina, CA, USA). All samples were grouped by individual with 
their age and sex-matched pair processed alongside. All samples were processed in a single batch of six 
BeadChips. Illumina Genome Studio software was used to extract the raw signal intensities of each probe 
(without background correction or normalization). 
2.3 Data Analysis  
All computations and statistical analyses were performed within the R statistical environment (version 
2.15.3) (R Development Core Team, 2012) and Bioconductor 2.14 (Gentleman, et al., 2004). Signal 
intensities were imported into R using the methylumi package (Davis, et al., 2012). Initial quality control 
checks (QC) were performed to assess concordance between reported and genotyped gender. Non-CpG 
SNP probes on the array were used to confirm that longitudinal samples were sourced from the same 
individual. Data was pre-processed using wateRmelon (version 1.4.0) using the dasen function as previously 
described (Pidsley, et al., 2013), with two samples being excluded at baseline for failing QC (Supplementary 
Table 1). Non-CpG SNP probes, non-specific probes, and probes that have been reported to contain 
common (MAF > 5%) SNPs in the CpG position or single base extension position were flagged and removed 
from analyses, leaving 388,850 probes (Chen, et al., 2013). 
We identified differentially methylated positions (DMPs) by comparing non-converters and converters at 
both baseline and 18 month follow-up using linear models at each time point separately, whilst controlling 
for the effects of age, sex, Hbac1 and years of education. The Genomic Regions Enrichment of Annotations 
Tool (GREAT) (McLean, et al., 2010) was used to annotate probes with genes within 5000bp upstream, and 
1000bp downstream.  Similarities of DNA methylation differences across datasets was assessed using 
Pearson’s correlation. Raw microarray data are available in the online Gene Expression Omnibus (GEO) 
(accession number: GSE62003). 
 
3. Results and Discussion 
The top-ranked DMPs at baseline and 18-month follow-up are shown in Supplementary Tables 2 and 3. A 
particular interest was the identification of stable DNA methylation differences between converters and 
non-converters, detectable at both time points. In this regard, it is notable that DNA methylation 
differences for the 100 top-ranked DMPs at baseline are strongly correlated with DNA methylation 
differences at the same probes at 18-month follow-up (Figure 1A; 0.856, P=5.84E-30). Similarly, DNA 
methylation changes for the 100 top-ranked DMPs at follow-up are strongly correlated with DNA 
methylation differences at the same probes at baseline (Figure 1B; r=0.872, P=1.49E-32). Furthermore, 
using a nominal p-value threshold (p≤0.001), we identified eight probes that were differentially methylated 
at both time points (Table 1; Supplementary Figure 1). This group of DMPs may represent early and 
consistent markers of cognitive change. Of these, four DMPs were hypermethylated in converters at both 
time points and four were hypomethylated at both time points. One of these probes is located in close 
proximity to RPL13. Interestingly DNA methylation in the vicinity of RPL13 has been previously associated 
with AD pathology in post-mortem brain (De Jager, et al., 2014,Lunnon, et al., 2014). Although the other 
identified loci have not been robustly associated with dementia, they could still represent novel 
biomarkers. We have previously shown that the most significant DMPs in blood between AD patients and 
non-demented control individuals are, as expected, very distinct from those seen in brain (Lunnon, et al., 
2014), and it is plausible that novel DMPs identified in this study represent a peripheral response by 
leukocytes to early disease changes in the brain, rather than a direct reflection of neuropathological 
changes observed in the brain. 
Having previously identified a number of CpG sites that are differentially methylated in whole blood in AD 
patients compared to elderly non-demented control subjects (Lunnon, et al., 2014), we were interested in 
investigating whether any of the DMPs identified in the current study overlapped with loci differentially 
methylated in clinically-diagnosed AD patients. We found no significant correlation between DNA 
methylation differences at the 100 top-ranked converter-associated DMPs at baseline with our previously 
reported AD-associated DMPs (Supplementary Figure 2; r=0.165, P=0.101). Interestingly, however, there 
was a significant correlation between DNA methylation differences at the top-ranked DMPs identified post-
conversion with differences seen at the same CpG sites between control and clinically-defined AD subjects 
(Supplementary Figure 3; r=0.32, P=1.29E-3). This indicates that the differences seen in converters at 
follow-up, after they display symptoms of pre-symptomatic dementia, reflect differences identified in 
clinically-presenting AD patients. Differences between converters and non-converters at baseline, however, 
are not seen in clinically-recognized AD patients. This reinforces the hypothesis that epigenetic differences 
identified in the blood from AD patients most likely reflect peripheral responses to the disorder, rather than 
causally-related variation. Such changes are, however, potentially useful as biomarkers of underlying 
neuropathology. 
 
4. Conclusions 
Given the predicted increase in dementia incidence, the identification of early and robust markers of 
disease, which are detectable prior to the emergence of clinical symptoms, is of upmost importance, 
particularly in ‘high risk’ groups. This study identified a number of DMPs in blood samples from T2D 
patients after they had developed pre-symptomatic dementia, which are also altered in white blood cells 
from AD patients, and could thus represent early markers of dementia. This study also demonstrated 
robust alterations at several CpG sites in blood samples from T2D patients at baseline who developed pre-
symptomatic dementia. These loci were altered prior to the emergence of clinical symptoms, and remained 
altered after conversion.  Interestingly one of these CpG sites reside close to a gene previously associated 
with dementia (RPL13) (De Jager, et al., 2014,Lunnon, et al., 2014).Although the other identified CpG sites 
have not been robustly associated before with dementia, they still could represent part of an early 
peripheral response to dementia and serve as potential biomarkers for early cognitive changes. Although 
the changes reported in this study do not reach genome-wide significance, this is not surprising given the 
relatively small number of samples. An optimum level of significance for epigenome-wide association 
studies (EWAS) has yet to be established, but given the non-independence of DNA methylation across CpG 
sites and the non-variable nature of most probes on the 450K array (Mill and Heijmans, 2013), it is likely 
that a Bonferroni correction is overly stringent. The intra-individual longitudinal repeated-measure design 
used in this study is relatively robust and controls for many potential confounders in epigenetic 
epidemiology. Although we were able to validate DMPs at two independent time points and in an 
independent study comparing non-demented control and clinically-diagnosed AD patients, future research 
is needed to validate the findings from this pilot study in larger independent sample cohorts, and to 
determine the exact specificity and timing of these changes.  
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Figure 1: Correlation of the % methylation differences for the 100 top-ranked DMPs across both time points. DNA methylation differences for the 100 most significant 
DMPs at baseline (shown in Supplementary Table 2) (X-axis) are significantly correlated (r=0.856, P=5.84E-30) with DNA methylation differences in the same probes at 18 
month follow up (Y-axis) (A). Similarly DNA methylation differences for the 100 most significant DMPs at 18 month follow-up (shown in Supplementary Table 3) (Y-axis) are 
significantly correlated (r=0.872, P=1.49E-32) with DNA methylation differences in the same probes at baseline (X-axis) (B). 
                                
